Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells by unknown
Sequential Immunizations with rgp120s from
Independent Isolates of Human Immunodeficiency
Virus Type 1 Induce the Preferential Expansion of
Broadly Crossreactive B Cells
By Dennis M. Klinman,* Keith W. Higgins, t
and Jacqueline Conover*
From the 'laboratory ofRetrovirus Research, Division of Virology, Centerfor Biologics
Evaluation and Researrh, Food and Drug Administration, Bethesda, Maryland 20892, and the
tChiron Corporation, Emeryville, California 94608
Summary
The gp120 envelope glycoprotein of humanimmunodeficiency virus type 1(HIV1) is a dominant
target against which the host's humoral immune response is directed. Unfortunately, gpl20 proteins
from different isolates of HIV are antigenically distinct, complicating the use of the envelope
glycoprotein in vaccines designed to prevent acquired immunodeficiency syndrome. Using an
enzyme-linked immunosorbent spot assay (ELISA), BALB/c mice immunized and boosted with
recombinant purified gp120 were studied at the single cell levelfor theirhumoral immune response
to HIV-1 envelope proteins. Approximately 90% ofresponding B cells produced antibodies reactive
with the immunizing form of gp120 but not with gp120s from other strains of HIV A novel
sandwich ELISA was then used to analyze the frequency with which individual in vivo activated
B cellsproduced antibodies that crossreacted with heterologous gp120s. Repeated immunizations
with a single gp120 or with a mixture of different gp120s resulted in the activation of primarily
mono-specific (noncrossreactive) B cells. In contrast, the sequential immunization of mice with
recombinant purified envelope proteins from different strains of HIV (IIIB, SF2, and Zr6) induced
the selective expansion of B cells producing highly crossreactive antibodies.
nfection with HIV-1 leads to a profound and progressive
impairment of T cell immunity and the development of
AIDS (1, 2). Considerable evidence suggests that the major
envelope glycoprotein of HIV-1 (gp120) mediates viralattach-
ment to human T cells via the lymphocyte's CD4 receptor
(3-5). Gp120 also acts as a dominant target against which
the host directs its humoral and cell-mediated immune re-
sponses (6). Thus, recombinant gp120 proteins are being
studied as potential immunogens in vaccines designed to pre-
vent AIDS (6-8).
An obstacle to the development of such a vaccine is the
pleiotropic nature of the gp120 molecule. Multiple variants
of HIV-1 expressing antigenically distinct envelope glycopro-
teinshave been described (9-12). Molecular analyses of these
divergent viruses show differences in up to 50% of the amino
acids expressed in the hypervariable regions of their gp120s
(13-17). These findings are consistent with the rapid muta-
tion rate described for HIV-1 and suggest that strong im-
munologically based selective pressures may be responsible
for the sequential outgrowth of distinct virus strains in
vivo (15).
An effective vaccine based upon gp120 must be capable
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of eliciting an immune response against a wide range ofHIV-1
envelope glycoproteins. Yet previous studies have shown that
immunizations with envelope protein derived from a single
isolate of HIV-1 generally did not induce a broadly crossreac-
tive antibody response (18-20). In the present work, a chamber
ELISA was developed to investigate the crossreactivity of in-
dividual B cells activated in mice immunized with gp120s
from different isolates of HIV Results indicate that 85-95%
of the B cells activated afterimmunization with a single iso-
late of gp120 reacted only with that isolate. In contrast, se-
quential immunization with divergent isolates of gp120 led
to the preferential expansion ofB cells producing highly cross-
reactive antibodies. These findings suggest that a protocol
based upon sequential immunization might achieve the ob-
jective of eliciting a broadly protective anti-HIV antibody
response.
Materials and Methods
Spleen Cell Preparation.
￿
Female BALB/c mice were obtained from
The Jackson Laboratory, Bar Harbor, ME. These mice were im-
munized intraperitoneally with 10 pg ofrecombinant env 2-3 from
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881-887the IIIB, SF2, and/or Zr6 strains of HIV-1 (Chiron Corporation,
Emeryville, CA) emulsifiedin CFA (21). The env 2-3 preparations
were full-length recombinant purified gp120 proteins (amino acids
28-509) and were produced in yeast strain 2150 under a GAP pro-
moter. Theseproteins were nonglycosylated and -90% pure. Pre-
liminary experiments demonstrated that 10 ug/animal induced a
primary gp120-specific humoral response in 100% of immunized
mice. Some animals were boosted at 6-8-wk intervals with env
2-3 in IFA. All animals were bled by retro-orbital puncture 4 wk
after primary immunization or 2 wk after boosting. A single cell
suspension was immediately made from the spleens of these animals
in medium consistingof RPMI 1640 supplemented with 2% FCS
(22). Serum was stored at -20° until assayed for the presence of
neutralizing and binding antibodies as described (23) .
Virus Neutralization Assay.
￿
500 tissue culture infectious doses
of HIV-1 virus were incubated for 90 min with heat-inactivated
mouse serum diluted 1:4 to 1:512 in microtiter plates. 1.5 x 10°
Molt-3 cells, whichhad been pretreatedin media containing2 lAg/ml
of polybrene, were then added. Plates were centrifuged at 700 g
for 45 min and placed in 37°C humidified 5% C02 for 5 d. 50%
inhibition of giant cell formation was taken as the endpoint for
virus inhibition. Well-to-well variation was <15% (23).
ELISAs.
￿
Flat-bottomed Immulon I microtiter plates (Dynatech
Labs, Alexandria, VA) were coated with optimal concentrations
of env 2-3 from IIIB, SF2, Zr6, or feline leukemia virus (FEW)'
(Chiron Corporation), or ssDNA, TNP-KLH, OVA, or rabbit
anti-mouse IgG (Cappel Laboratories, Cochranville, PA) and then
blocked with 1% BSA in PBS as previously described (21, 24, 25).
A 1:20 dilution of sera derived from blood clotted at 37°C for 90
min was incubated on antigen (Ag)-coupled plates for 2 h. Un-
bound Ig was washed away with PBS/0.05% Tween 20. Alkaline
phosphatase-conjugated anti-mouse IgG (Southern Biotechnology
Associates, Birmingham, AL) was added for 2 h. The plates were
then washed and assayed colorimetrically for the presence ofbound
antibody (Ab). The concentration ofspecific Ab bound to the plates
was determined by comparison to a standard curve generated using
known dilutions ofhigh titered antisera, as previouslydescribed (22).
Spot ELISAs.
￿
Serial dilutions of single cell suspensions made
from the spleens of immunized mice, starting with 106 cells/well,
were incubated for 6 h on antigen-coated plates in 5% C02 in an
air incubator at 37°C. The cells were removedby washing the plate
with PBS/0.05% Tween 20, and the wells were overlaid with
phosphatase-conjugated anti-mouse IgG antibody for 2 h. The an-
tibodies produced by individualB cells that bound to the plate were
visualized by addition of a 5-bromo-3-chloro 4-indolyl phosphate
solution (Sigma Chemical Co., St. Louis, MO) in a low-melt agarose
kept at 50°C. Phosphatase acts on this substrate to produce a blue
spot that cannot diffuse through the agarose once it solidifies at
room temperature (26). That dilution of cells producing -30
spots/well was used to quantitate the total number of antibody-
specific B cells per sample. The presence of BSA in the FCS used
to conduct theseassays inhibited the binding ofBSAspecific anti-
bodies to BSAblock plates, giving the assay a zero background.
The sensitivity and specificity ofthis assay was documented by an-
tigen inhibition tests and in studies involving antigen-specific hy-
bridoma cell lines (26-28; and data not shown).
Sandwich ELISA Technique.
￿
Plastic microscope slides (Thomas
Scientific, Philadelphia, PA) were coated with antigen and blocked
with 1% BSA by the procedures described above for coating mi-
crotiter plates. Sandwich ELISA chambers were constructed by
' Abbreviations used in this paper: Ab, antibody; Ag, antigen, FEW, feline
leukemia virus.
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taping two antigen-coated slides together using strips of Scotch
Brand double-sided tape (3M Co., St. Paul, MN). Four equally
spaced strips of tape were used to create three independent com-
partments per chamber (see Fig. 1). Approximately 50 pl ofa single
cell suspension containing 101, 106, or 105 cells/ml was pipetted
into these compartments and the chamber placed in humidified
5% C02 in an air incubator at 37°C for 10 h. The chamber was
then split apart and processed as described in the spot ELISA de-
scribed above.
After processing, the number ofspots per compartment on each
slide was counted. The two slides were thenjuxtaposed (through
use ofalignment markings placed on each slide before incubation),
and overlapping spots (representing antibodies that reacted with
antigen onboth slides) were quantitated. The percent ofcrossreac-
tive B cells for each set of antigens was determined independently
in at least three mice per experiment. All experiments were per-
formed at least twice.
Results
Serum Antibody Levels after rgp120 Immunization.
￿
BALB/c
mice were immunized with rgp120 (env 2-3 preparation) from
the IIIB, SF2, or Zr6 strains of HIV1. The serum antibody
response of these mice was analyzed after 4 wk (preliminary
studies showed that maximal IgG anti-gp120 productionwas
present at this time). Whereas 100% of these mice devel-
oped significantly elevated serum IgG antibody titers to the
immunizing isolate of rgp120, only 33-83% of these animals
produced antibodies that bound to gp120s expressed by other
HIV isolates (Table 1). In addition, the concentration of an-
tibody reactive with the immunizing gp120 was 15-30-fold
higher than that against envelope proteins from other HIV
strains. Secondary immunization increased the totalanti-gp120
response but not the relative proportion of antibodies reac-
tive with heterologous gp120 (Table 1) . It also induced a low-
titered (1:8 to 1:32) neutralizing antibody response that was
type specific (i.e., neutralization was specific for the HIV-1
strain from which the gp120 was derived).
Number andSpecificity ofB Cells Producing Antibodies against
rgp120. The concentration of anti-gp120 antibodies in serum
reflects the time-averaged balance between theirrate ofproduc-
tion and degradation. To directly measure the ongoing re-
sponse to gp120, a spot ELISA was used to monitor the
number and specificity ofB cells actively secreting Ig in vivo.
As seen in Table 2, normal BALB/c mice had no splenic
B cells producing IgG antibodies reactive with rgp120. In
contrast, 4-9% of all IgG-secreting cells from gp120-
immunized mice secreted antibodies reactive with the im-
munogen. These cells did not react with the unrelated an-
tigens OVA, TNP-KLH, or DNA, or with gp120 from FEW
(an env 2-3 preparation produced by the same process used
to make gp120 from HIV-1). Consistent with the aboveserum
studies, only a small fraction ofB cells from immunized mice
produced antibodies capable ofbinding to heterologous forms
of envelope protein (Table 2).
Mice were then primed and boosted twice with the same
rgp120. 11-19% of the IgG-secreting splenic B cells from
multiply immunized mice produced antibodies reactive with
the immunogen (Table 3). While some broadening of theTable 1.
￿
Specificity ofSerum Antibodies from rgp120-immunized Mice
Mice were immunized with 10 hg of env 2-3 in CFA and bled 4 wk later. Ab concentration was determined in comparison to a standard curve
generated using a high titered antiserum of known specificity. A minimum of six mice/group were independently examined.
A mouse was considered antibody positive if its serum yieldedan anti-gp120 concentration that exceeded the mean of unimmunized mice by >2 SD.
reactivity pattern was noted, on average, <10% of these
gpl20-specific B cells produced antibodies reactive with het-
erologous gpl20s (Table 3).
Crossreactivity ofAntigp120producing BCells.
￿
An assaywas
developed to identify andquantitate in vivo activated B cells
secretingcrossreactive anti-gp120 antibodies. Freshly isolated
splenic lymphocytes from immunized mice were sandwiched
betweenplastic slides that hadbeen coated with env2-3 from
the IIIB, SF2, or Zr6 strains of HIV-1 (see Fig. 1). In vivo
activated B cells continued to secrete Ig when incubated for
10 h in these sandwich ELISA chambers and produced anti-
Six mice/group were immunizedintraperitoneally with 10 t~gof env2-3
or PBSin CFA. 4 wk later, spot ELISAwas used to determinethenumber
of B cells producing IgGantibodies reactive with each rgp120. The per-
cent of cells secreting antibodies of each specificity was calculated as a
function of the absolute number of IgG-producing cells per spleen by
the formula: 100x (no. of IgG anti-gp120-secreting cells/total no. of
IgG-secreting cells). It should be noted that Bcells from mice immunized
with rgp 120TH also bound to gp160 (Microgenesis, West Haven, CT)
and total viral lysates (DuPont Co., Wilmington, DE) produced from
that isolate.
' In all experiments, B cells were tested for reactivity with control anti-
gens (DNA, TNP-KLH, andOVA). Resultsrepresented thehighestback-
ground reactivity detected against any of these antigens.
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bodies that bound to the antigens coating one or both sides
of the chamber. In preliminary experiments, both sides of
a chamberwere coated with the same rgp120. SplenicB cells
from mice immunized with that antigen (but not naive
animals) generated ELISA spots in precisely the same posi-
tion on both sides of the chamber (visualized by superim-
posing but slightly offsettingthe slides, as illustrated in Fig.
1). When OVArather than gp120 was used to coat one side
of the chamber, there was no concordancebetween theloca-
tion of the ELISA spots produced. Similarly, no crossreac-
tivity was detected when chambers were constructed using
slides coated with env 2-3 from FEW as theantigen on one
side and env 2-3 from HIVniB on the other. These findings
indicate that: (a) B cells producing crossreactive antibodies
produced ELISA spots in the same position on both sides
of an ELISA chamber, whereas mono-specific B cells pro-
duced spots on only one side of the chamber (Fig. 1); (b)
spot formation was antigen specific (a finding confirmedby
Table 3.
￿
gp120 Reactivity of B Cells from Multiply
Immunized Mice
Six mice/group were immunizedintraperitoneallywith 10 jAgof rgp120
in CFA. 8 and 14 wk later, they were boosted with the same immu-
nogen in IFA. A spot ELISA was performed as describedin the legend
of Table 3 2 wk after the final immunization.
Immunizations
Percent
IIIB
of mice Ab positive*
SF2 Z6 IIIB
Reciprocal Ab concentration
SF2 Z6
Primary
IIIB 100 83 33 1,280 38 20
SF2 50 100 33 36 980 46
Z6 33 33 100 22 24 880
Secondary
IIIB 100 83 50 16,400 160 126
SF2 67 100 50 300 6,800 210
Z6 67 50 100 156 144 28,000
Table 2. Reactivity of B Cells from rgp120-immunized Mice
Percent IgG-secreting cells reactive with:
Immunogen IIIB SF2 Z6 FELV Other"
IIIB 6.5 0.56 0.28 0 0
SF2 0.39 9.8 0.83 0 0
Z6 0.65 0.26 4.4 0 0
FELV 0 0 0 4.7 0
PBS 0 0 0.12 0 0 Percent IgG-secreting cells reactive with:
Immunogen IIIB SF2 Z6 FELV Other
IIIB 12.18 0.91 0.81 0.06 0.08
SF2 0.82 18.52 2.38 0.00 0.00
Z6 1.67 0.88 10.53 0.18 0.12
FELV 0.00 0.14 0.00 11.76 0.00Figure 1 .
￿
Chamber ELISA . (A) Plastic microscope slides were coated
with antigen and secured together using double-sided tape to form an
ELISAchamber. Freshlyisolated splenic lymphocytes were added between
the slides to form a monolayer. Chambers were then placed in a humidified
5% CO2 in-air incubator for 10 h . Antibodies produced by in vivo acti-
vated B cells bound to the antigen-coated slides and were visualized by
a conventional colorimetric spot developing ELISA . (B) The number of
spots on each slide, representing the number ofB cellsproducing antigen-
specific antibodies, were then counted . If the same antigen was used to
coat both sides of an ELISA chamber, 100% of the spots present on one
slide were present in the same position on the other slide. Crossreactive
B cells were detected by the appearance ofELISA spots in the same posi-
tion on slides that had been coated with different antigens .
testing hybridomas ofknown antigenic specificityand in Ag
inhibition tests ; data not shown) ; and (c) low-level contami-
nation of the env 2-3 preparations with yeast-derived impu-
rities (<10% by weight) was not responsible for the B cell
stimulation detected in this assay, since activatedB cells did
not crossreact with gp120 from FELV.
WhenBcellsfrom immunizedmice were analyzed in sand-
wich ELISA chambers, only 2-15% of lymphocytes reactive
with the immunizing form of gp120 crossreacted with het-
erologous gp120s (Table 4) . Repeatedly boosting mice with
a single isolate of gp120 did not increase the proportion of
crossreactive B cells (although it did increase the absolute
number ofB cellsproducing antibodies against heterologous
gp120s ; Table 5) .
Selection ofCrossreactive B Cells by Sequential Immunization
with Distinct rgp120 Isolates. The above findings suggested
that immunization protocols using envelope proteins from
a single isolate of gp120 would be limited in their ability
to promote the outgrowth of crossreactive B cells . In an at-
tempt to preferentially activate crossreactivelymphocytes, mice
were immunizedsequentially with rgpl20s from different virus
strains. As seen in Table 6, this strategy resulted in the preferen-
tial activation/proliferation of crossreactive lymphocytes. Mice
immunized with gp120HIB and boosted with gpl20sr2 ex-
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Table 4 .
￿
Crossreactivity of B Cells from rgp120-immunized
Mice Detected by Chamber ELISA
Percent crossreactivity between
immunogen and :
Percent gp120-
Immunogen reactive cells
￿
IIIB
￿
SF2
￿
Z6
￿
FELV Other
IIIB
￿
6.7 100 8.8 2 .3 0 0
SF2
￿
10.3
￿
5 .5 100
￿
15 .5 0
￿
0
Z6
￿
4.8
￿
12 .5 8.8 100
￿
0
￿
0
Sandwich ELISA chambers were constructed in which one side was coated
with the immunizing antigen and the other with rgp120 from a different
isolate of HIV-1 . Freshly isolated splenic lymphocytes from immunized
mice were cultured in these chambers for 10 h . The number of spots
per slide was counted (cell numbers yielding no greater than 125 spots/side
were used) . The two sides of the chamber were then superimposed and
spots present in the same location on both (representing crossreactive B
cells) counted .To determine the assay background (representing the chance
appearance of two spots in the same position on both sides), slides from
two different chambers were superimposed . This background (average
of 0.3 spots/chamber) was subtracted from all data . Results represent
the mean of at least two independent experiments involving aminimum
of three independently studied mice per group .
Table 5.
￿
Crossreactivity of B Cells from Multiply Immunized
Mice Detected by Chamber ELISA
Immunization schedule was described in the legend of Table 3, and the
assay was conducted as described in the legend of Table 4.
pressed a repertoire in which -40% of Ag-specific B cells
reacted with all gp120s examined, including Zr6 . The ex-
pansion of crossreactive B cells was furtherenhanced by im-
munizing sequentially with all three gpl20s in turn (Table
7) . While we could not determine the neutralizing capacity
of the antibodies secreted by individual B cells, serum from
sequentially immunized mice neutralized theMN strain of
HIV -1 whereas serum from mice immunized with a single
isolate of gp120did not (Table 6) . The preferential induction
ofcrossreactiveB cells apparently depended upon the sequential
presentation of rgp120 antigens, since repeated immuniza-
tion with a single mixture containing all three gpl20s did
not lead to the selective proliferation of these cells (Table 7) .
Percent crossreactivity between
Immunogen
Percent gp120-
reactive cells IIIB
immunogen
SF2
and :
Z6 FELV
IIIB 12 .7 100 6 .8 3 .9 0.4
SF2 19 .1 3 .7 100 13 .4 0.0
Z6 11 .0 8.2 5 .4 100 0.3
FELV 11 .8 0.0 0.7 0.0 100Mice were immunized intraperitoneally with 10 NAg of rgp120111B. 8 wk later, these animals were immunized/boosted with the antigen shown in
the first column. The percent of IgG anti-gp120-secreting cells was quantitated 2 wk later by spot ELISA as described in Table 2. Crossreactivity
was studied simultaneously using a chamber ELISA, as described in Table 4. Data represent results of two independent experiments involving three
independently studied mice per group. Background crossreactivity with rgp120 from FELV was <0.2%.
Sera from these mice were analyzed for the presence of neutralizing antibodies. A+ indicates neutralizing titers >_ 1 :16 against both the MN and
IIIB strains of HIV-1 (23) .
Table 7.
￿
Expansion ofCrossreactive B Cells Requires Sequential
Immunization with Divergent gp120s
Immunization
￿
Percent crossreactive
sequence
￿
with IIIB
Percent gp102-
See legend to Table 4 for experimental details. Data in the last row
represent mice immunized with a mixture containing 5 tag/isolate of each
rgp120.
Discussion
The possibility that recombinant gp120 could be used in
a vaccine to prevent HIV-1 infection has attracted consider-
able interest (6-8, 29). In the present work, the immuno-
genicity and crossreactivity ofrecombinant gp120s from var-
ious HIV strains was examined in BALB/c mice. Results
indicate that -90% of the B cells responding to envelope
proteins from a single isolate of gp120 produced antibodies
that reacted with that isolate but not with gp120s from other
strains ofHIV Boosting with the same gp120 induced serum
antibodies with increased binding to heterologous isolates.
However, this was due to an increase in the number (and
perhaps affinity) of anti-gpl20-producing cells rather than
an increase in the frequency of crossreactive B cells. By com-
parison, sequential immunization of mice with rgp120s from
different isolates of HIV-1 led to the preferential expansion
of lymphocytes producing antibodies that crossreacted with
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a variety of rgpl20s but not with unrelated antigens. These
findings indicate that a vaccination protocol involving sequen-
tial immunization might optimize the productionofa broadly
protective anti-HIV humoral response.
A number of investigators have shown that animals im-
munized with nonglycosylated gp120 produce strain-specific
neutralizing antibodies (8, 29). For example, goats immunized
with gpl201llB produced antibodies that neutralized HIVt11B
but not HIVRE, and vice versa (30, 31). By comparison,
non-neutralizing antibodies from similarly immunized animals
showed a limited degree of crossreactivity, suggesting that
non-neutralizing antibodies might differ in concentration,
affinity, and/or epitope specificity from those with neutralizing
capacity (31). In the present report, serum from sequentially
immunized mice neutralized the MN virus at titers ranging
from 1:16 to 1:128. In contrast, serum from mice repeatedly
immunized with a single isolate (or mixture) of gp120s did
not produce detectable crossneutralizing antibodies. Similarly,
we found that sera from sequentially immunized mice bound
to rgp120s from multiple different isolates of HIV1, whereas
sera from mice immunized multiple times with a single rgp120
reacted predominantly with only that isolate of envelope gly-
coprotein.
The crossreactivity detected in serum could have been due
to the presence of. (a) multiple antibody populations, each
specific for a different rgp 120; (b) highly crossreactive anti-
bodies capable of binding to numerous unrelated antigens
(such as have been described in various autoimmune states);
or (c) antibodies specific for epitope(s) shared by different iso-
lates of HIV-1. To differentiate among these possibilities, a
novel sandwich spot ELISA was developed to detect individual
in vivo activated B cells secreting crossreactive antibodies. This
assay was a significant improvement over previous techniques
used to study B cell crossreactivity. It did not require the
mitogen stimulation or cloning of B cells and thus elimi-
nated the possible repertoire bias introduced by such in vitro
manipulations. Unlike the technique of Cunningham and
Pilarski (32), the chamber ELISA yielded a permanent record
of results, was simple to perform, and couldbe used to study
10 20 30 reactive cells SF-2 Z6 Other
IIIB IIIB III13 12.2 2.8 3.9 0
IIIB SF2 Z6 18.3 31.0 22.2 0
IIIB Z6 SF2 26.6 42.8 33.3 0
SF2 IIIB Z6 16.8 42 .6 66.7 0
Z6 III13 SF2 21.9 57.6 34.3 0
All All All 5 .1 3 .5 0
Table 6. Effect
IIIB Immunized,
boosted with:
ofSequential Immunization
Percent gp120
reactive
on B Cell Crossreactivity
Neutralizing
Abs"
Percent
IIIB
crossreactivity between
SF2
boosting
Z6
rgp120 and:
Other
IIIB 8.4 - 100 3.2 2.2 0
SF2 15.1 + 37.7 100 39.5 0
Z6 10.0 + 40.7 21.2 100 0antibodies of different isotypes reactive with a wide variety
of antigens. The specificity and sensitivity of this assay was
similar to that of conventional spot ELISAs (shown by an-
tigen inhibition tests and assays usinghybridomas of known
antigenic specificity; data not shown). Using this assay, we
found that at least 90% of the responding B cells from mice
immunized with one isolate of rgp120 were reactive only with
that isolate. Multiple immunizations did not increase the
proportion of B cells secreting crossreactive antibodies.
That only a small proportionofB cells activated after im-
munization with a single isolate of gp120 were crossreactive
is consistent with results from other laboratories showing
that conserved regions are less immunogenic than hypervari-
able regions on the gp120 molecule (16, 29, 33-35). Indeed,
recent findings suggest that antibodies against conserved
regions cannot be induced unless hypervariable regions are
also present (21) - a phenomenon that may be associated
with the recognition ofhypervariable regions by T cells (36) .
A major goal in the development of an HIV vaccine is
the induction of antibodies capable of recognizing all pos-
sible strains of virus (31) . Unfortunately, achieving this ob-
jective has been complicated by the high degree of polymor-
phism expressed by HIV-1 envelope proteins (16) and the poor
immune response generated against conserved gp120 deter-
minants (21, 29). To circumvent this problem, we sequen-
tially immunized mice with different isolates ofgp120. Results
indicate that sequential immunization induced the specific
expansion of B cells secreting IgG antibodies that crossreacted
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